Interventional pain modalities provide alternative analgesia in patients who are intolerant of pharmacologic agents, have comorbidities that require multiple medications, or have pain refractory to oral medications.
Production and distribution of Excedrin Extra Strength and Excedrin Migraine products have been temporarily stopped, maker GlaxoSmithKline said Tuesday.
The Food and Drug Administration (FDA) has approved Ubrelvy (ubrogepant tablets; Allergan), the first oral calcitonin gene-related peptide (CGRP) receptor antagonist, for the acute treatment of migraine with or without aura in adults.
